MX2021014705A - Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento. - Google Patents
Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento.Info
- Publication number
- MX2021014705A MX2021014705A MX2021014705A MX2021014705A MX2021014705A MX 2021014705 A MX2021014705 A MX 2021014705A MX 2021014705 A MX2021014705 A MX 2021014705A MX 2021014705 A MX2021014705 A MX 2021014705A MX 2021014705 A MX2021014705 A MX 2021014705A
- Authority
- MX
- Mexico
- Prior art keywords
- modified release
- treatment
- methods
- pyrimidinylamino
- release formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción se refiere a formulaciones de liberación modificada de 2-metil-2-(3-metil-4-(4-(metilamino)-5-(trifluoromet il)pirimidin-2-ilamino)-1H-pirazol-1-il)propanonitrilo o solvatos, tautómeros y sales farmacológicas aceptables de este, y métodos de tratamiento con las formulaciones de liberación modificada. 1. Una formulación de liberación modificada que comprende una cantidad terapéuticamente eficaz de 2-metil-2-(3-metil-4-(4-(metilamino)-5-(trifluorometil)pirimidin- 2-ilamino)-1H-pirazol-1-il)propanonitrilo y al menos un agente que modifica la liberación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962855740P | 2019-05-31 | 2019-05-31 | |
PCT/US2020/035413 WO2020243635A1 (en) | 2019-05-31 | 2020-05-29 | Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014705A true MX2021014705A (es) | 2022-04-06 |
Family
ID=73553940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014705A MX2021014705A (es) | 2019-05-31 | 2020-05-29 | Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220249479A1 (es) |
EP (1) | EP3975719A4 (es) |
JP (1) | JP2022535748A (es) |
KR (1) | KR20220015437A (es) |
CN (1) | CN114126408A (es) |
AU (1) | AU2020282348A1 (es) |
BR (1) | BR112021024194A2 (es) |
CA (1) | CA3139155A1 (es) |
EA (1) | EA202193285A1 (es) |
IL (1) | IL288406A (es) |
MA (1) | MA56063A (es) |
MX (1) | MX2021014705A (es) |
SG (1) | SG11202112464PA (es) |
TW (1) | TW202110453A (es) |
WO (1) | WO2020243635A1 (es) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
US9198871B2 (en) * | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
PT2638031T (pt) * | 2010-11-10 | 2018-01-03 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de lrrk2 |
MX349556B (es) * | 2011-11-29 | 2017-08-03 | Genentech Inc | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). |
BR112018075569A2 (pt) * | 2016-06-16 | 2019-03-19 | Denali Therapeutics Inc. | pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
-
2020
- 2020-05-29 SG SG11202112464PA patent/SG11202112464PA/en unknown
- 2020-05-29 EP EP20814049.1A patent/EP3975719A4/en active Pending
- 2020-05-29 KR KR1020217042629A patent/KR20220015437A/ko unknown
- 2020-05-29 CA CA3139155A patent/CA3139155A1/en active Pending
- 2020-05-29 BR BR112021024194A patent/BR112021024194A2/pt unknown
- 2020-05-29 AU AU2020282348A patent/AU2020282348A1/en active Pending
- 2020-05-29 TW TW109118205A patent/TW202110453A/zh unknown
- 2020-05-29 MA MA056063A patent/MA56063A/fr unknown
- 2020-05-29 MX MX2021014705A patent/MX2021014705A/es unknown
- 2020-05-29 JP JP2021570372A patent/JP2022535748A/ja active Pending
- 2020-05-29 US US17/614,842 patent/US20220249479A1/en active Pending
- 2020-05-29 EA EA202193285A patent/EA202193285A1/ru unknown
- 2020-05-29 WO PCT/US2020/035413 patent/WO2020243635A1/en unknown
- 2020-05-29 CN CN202080051417.4A patent/CN114126408A/zh active Pending
-
2021
- 2021-11-25 IL IL288406A patent/IL288406A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020282348A1 (en) | 2021-12-02 |
US20220249479A1 (en) | 2022-08-11 |
IL288406A (en) | 2022-01-01 |
WO2020243635A1 (en) | 2020-12-03 |
EP3975719A1 (en) | 2022-04-06 |
EA202193285A1 (ru) | 2022-03-04 |
CN114126408A (zh) | 2022-03-01 |
BR112021024194A2 (pt) | 2022-01-11 |
SG11202112464PA (en) | 2021-12-30 |
MA56063A (fr) | 2022-04-06 |
TW202110453A (zh) | 2021-03-16 |
JP2022535748A (ja) | 2022-08-10 |
KR20220015437A (ko) | 2022-02-08 |
EP3975719A4 (en) | 2023-07-05 |
CA3139155A1 (en) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016010213A (es) | Formulaciones farmaceuticas novedosas. | |
MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
MY195002A (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
CR20210281A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr | |
PH12019500202A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX2019001308A (es) | Moduladores nmda espiro-lactam y metodos de uso de los mismos. | |
PH12019500207A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12019500206A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
PH12017500724A1 (en) | Carbazole derivatives | |
EA201290976A1 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
MX2019001322A (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
MX2018004664A (es) | Antagonistas de ep4. | |
WO2019169333A8 (en) | Afibrotic compounds, devices, and uses thereof | |
MX2022007285A (es) | Compuestos, polimeros, dispositivos y usos de los mismos. | |
SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
PH12021550687A1 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
EP3906030A4 (en) | COMPOSITIONS AND METHODS OF USE OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE | |
CO2022008012A2 (es) | Antagonistas heterocíclicos de nmda | |
EA202091279A1 (ru) | Полиморфы и твердые формы пиримидиниламино-пиразолового соединения и способы их получения | |
MX2021014705A (es) | Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento. |